[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585516":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":11,"armGroups":22,"interventions":34,"overallOfficials":49,"centralContacts":53,"locations":59,"responsibleParty":76,"collaborators":11,"id":78,"slug":11,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":11,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":94,"conditions":95,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Adverse Event (AE)",null,"Up to 2 years",[14],{"measure":15,"description":11,"timeFrame":12},"Objective response rate (ORR)",{"allocation":17,"interventionModel":18,"interventionModelDescription":11,"primaryPurpose":19,"observationalModel":11,"timePerspective":11,"maskingInfo":20},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":21,"maskingDescription":11,"whoMasked":11},"NONE",[23,30],{"label":24,"type":25,"description":26,"interventionNames":27},"Part1-Group A","EXPERIMENTAL","ZG005 20mg\u002Fkg IV Q3W+Gecacitinib 50mg po Bid",[28,29],"Biological: ZG005 for Injection","Drug: Gecacitinib Hydrochloride Tablets",{"label":31,"type":25,"description":32,"interventionNames":33},"Part1-Group B","ZG005 20mg\u002Fkg Q3W+Gecacitinib 100mg po Bid",[28,29],[35,42],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"BIOLOGICAL","ZG005 for Injection","intravenous infusion",[24,31],[41],"ZG005",{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"DRUG","Gecacitinib Hydrochloride Tablets","Oral",[24,31],[48],"Gecacitinib",[50],{"name":51,"affiliation":5,"role":52},"Jason Wu","STUDY_CHAIR",[54],{"name":55,"role":56,"phone":57,"phoneExt":11,"email":58},"Cong Zhang","CONTACT","17602176888","zhangc@zelgen.com",[60],{"facility":61,"status":62,"city":63,"state":64,"zip":11,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Shanghai Chest Hospital","RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":68,"coordinates":69},"Point",[70,71],121.45806,31.22222,{"lat":71,"lon":70},[74],{"name":75,"role":56,"phone":11,"phoneExt":11,"email":11},"Xinghao Ai",{"type":77,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100585516",false,"NCT06903377","Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I\u002FII Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Fully understand this study and voluntarily sign the ICF.\n* Age 18-75 years, no gender restriction.\n* Patients with locally advanced or recurrent\u002Fmetastatic squamous and\u002For non-squamous non-small cell lung cancer confirmed by histology\u002Fcytology, unsuitable for radical therapy.\n\nExclusion Criteria:\n\n* Medical history, CT scan, or MRI indicates the presence of CNS metastases.\n* Other malignancies within 5 years.\n* Any other reason deeming the participant unsuitable for the study, as judged by the investigator.","ALL","18 Years","75 Years",{"count":88,"type":89},50,"ESTIMATED","INTERVENTIONAL",[92,93],"PHASE1","PHASE2","This is a multicenter Phase I\u002FII study for patients with advanced non-small cell lung cancer who have failed PD-1\u002FL1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.",[96],"Non-small Cell Lung Cancer","2025-12-30",{"date":99,"type":100},"2026-01-05","ACTUAL",{"date":102,"type":100},"2025-05-23",{"date":104,"type":89},"2027-05",{"name":5,"class":6},1]